

DECLARATION IN SUPPORT OF A
CONVENTION APPLICATION FOR A PATENTIn support of the Convention Application made for a
patent for an invention entitled:

7-273-PCT-AUS-(GDM)

Title of Invention

Fluorescent Conjugates and Biological Diagnostic Assay

Full name(s) and
address(es) of
Declarant(s)I/~~WX~~ Gaetano D. Maccarone
of 549 Technology Square
Cambridge, Massachusetts 02139
United States of America

do solemnly and sincerely declare as follows:-

Full name(s) of
Applicant(s)

1. I am/~~We are~~ the applicant(s) for the patent
(or, in the case of an application by a body corporate)
1. I am/~~We are~~ authorised by

P B DIAGNOSTIC SYSTEMS, INC.

the applicant(s) for the patent to make this declaration on
its/~~their~~ behalf.

2. The basic application(s) as defined by Section 141 of the
Act was/~~were~~ made

Basic Country(ies)

in United States of America

Priority Date(s)

on April 2, 1987

Basic Applicant(s)

by Michael J. Arnost, Frank A. Meneghini,
Paul S. Palumbo and Stephen G. StroudFull name(s) and
address(es) of
inventor(s)

3. I am/~~We are~~ the actual inventor(s) of the invention referred
to in the basic application(s)
(or where a person other than the inventor is the applicant)

3. Michael J. Arnost, Frank A. Meneghini,
Paul S. Palumbo and Stephen G. Stroud

of 29 Paddock Lane, No. Andover, MA 01845; 123 Claremont Ave.,
Arlington, MA 02174; 271 Cherry Street, West Newton, MA
02165 and 15 Dunbar Avenue, Medford, MA 02155, United
States of America (respectively)is/are the actual inventor(s) of the invention and the facts upon
which the applicant(s) is/~~are~~ entitled to make the application are
as follows:Set out how Applicant(s)
derive title from actual
inventor(s) e.g. The
Applicant(s) is/are the
assignee(s) of the
invention from the
inventor(s)Said Corporation is the assignee of the actual
inventors

4. The basic application(s) referred to in paragraph 2 of this
Declaration was/~~were~~ the first application(s) made in a Convention
country in respect of the invention(s) the subject of the application.

Cambridge,

Declared at Massachusetts this 22nd day of August 1988

Gaetano D. Maccarone
Signature of Declarant(s)
Gaetano D. Maccarone, Attorney

11/81

(12) PATENT ABRIDGMENT (11) Document No. AU-B-17281/88
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 602090

(54) Title
FLUORESCENT CONJUGATES AND BIOLOGICAL DIAGNOSTIC ASSAY

International Patent Classification(s)
(51)⁴ **C09B 057/00 G01N 033/52 G01N 033/533 G01N 033/577**

(21) Application No. : **17281/88** (22) Application Date : **23.02.88**

(87) WIPO Number : **WO88/07682**

(30) Priority Data

(31) Number (32) Date (33) Country
034225 02.04.87 US UNITED STATES OF AMERICA

(43) Publication Date : **02.11.88**

(44) Publication Date of Accepted Application : **27.09.90**

(71) Applicant(s)
PB DIAGNOSTIC SYSTEMS, INC.


(72) Inventor(s)
MICHAEL J. ARNOST; FRANK A. MENEHINI; PAUL S. PALUMBO; STEPHEN G. STROUD

(74) Attorney or Agent
SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001

(56) Prior Art Documents
US 4622400
EP 050684

(57) Claim

1. A fluorescent diagnostic assay comprising combining in an assay medium: a sample suspected of containing an analyte; and members of a signal producing system; one of said members comprising a conjugate of a member of a specific binding pair and a fluorescent compound, said conjugate represented by the formula



wherein W, X, Y and Z each independently is $-(CH_2)_a(CHR_4)_b-$;
R, R_1 , R_3 and R_4 each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety;
 R_2 is $-CO_2^-$, $-SO_3^-$ or a substituent including a biologically active moiety;

provided that at least one of R, R_1 , R_2 , R_3 and R_4 is a substituent including said biologically active moiety and at least one of the remaining R, R_1 , R_3 and R_4 is said hydrophilic group;

a and b each independently is an integer of from 0 to 4, provided that the sum of a + b is an integer of from 1 to 4;

m and n each is 0 or 1 provided that one of m and n is 0 and the other is 1;

p and q each is 0 or 1 provided that one of p and q is 0 and the other is 1;


A is a counterion or the counterions to balance the overall charges on the conjugate moiety; and x is 0 or 1; and

separating bound conjugate from free conjugate;

measuring the level of the fluorescent signal of said bound or free conjugate; and

relating said level of said signal to the amount of said analyte in said sample.

2. The assay as defined in claim 1 wherein said conjugate is represented by the formula




(11) AU-B-17281/88
(10) 602090

-3-

where R_{12} , R_{13} , R_{14} and R_{15} each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said biologically active moiety and at least one of the remaining of R_3 , R_{12} , R_{13} , R_{14} and R_{15} is said hydrophilic group.

7. The assay as defined in claim 1 wherein said conjugate is represented by the formula



wherein R_{12} , R_{13} , R_{14} and R_{15} each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said biologically active moiety and at least one of the remaining of R_3 , R_{12} , R_{13} , R_{14} and R_{15} is said hydrophilic group.


8. The assay as defined in claim 7 wherein R_2 is a substituent including a biologically active moiety.

9. The assay as defined in claim 8 wherein R_{12} is a substituent including a hydrophilic group.

16. A diagnostic assay element adapted to receive a sample of a biological fluid and to provide a detectable signal as a function of an analyte which may be present in said fluid, said assay element including a fluorescent conjugate represented by the formula

(11) AU-B-17281/88
(10) 602090

-4-



wherein W, X, Y and Z each independently is $-(CH_2)_a(CHR_4)(CH_2)_b-$;

R, R₁, R₃ and R₄ each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety;

R₂ is $-CO_2^-$, $-SO_3^-$ or a substituent including a biologically active moiety;

provided that at least one of R, R₁, R₂, R₃ and R₄ is a substituent including said biologically active moiety and at least one of the remaining of R, R₁, R₃ and R₄ is a substituent including said hydrophilic group;


a and b each independently is an integer of from 0 to 4, provided that the sum of a + b is an integer of from 1 to 4;

m and n each is 0 or 1 provided that one of m and n is 0 and the other is 1;

p and q each is 0 or 1 provided that one of p and q is 0 and the other is 1;

A is a counterion or the counterions to balance the overall charges on the conjugate moiety; and x is 0 or 1.

30. A fluorescent conjugate represented by the formula



wherein W, X, Y and Z each independently is $-(CH_2)_a(CHR_4)(CH_2)_b-$;
R, R₁, R₃ and R₄ each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety;
R₂ is $-CO_2^-$, $-SO_3^-$ or a substituent including a biologically active moiety;
provided that at least one of R, R₁, R₂, R₃ and R₄ is a substituent including said biologically active moiety and at least one of the remaining R, R₁, R₃ and R₄ is a substituent including said hydrophilic group;
a and b each independently is an integer of from 0 to 4, provided that the sum of a + b is an integer of from 1 to 4;
m and n each is 0 or 1 provided that one of m and n is 0 and the other is 1;
p and q each is 0 or 1 provided that one of p and q is 0 and the other is 1;
A is a counterion or the counterions to balance the overall charges on the conjugate moiety; and x is 0 or 1.

International Bureau
602090
PUBLISHED UNDER THE PATENT



WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

(51) International Patent Classification⁴ : G01N 33/533, 33/52 C07D 491/14		A1	(11) International Publication Number: WO 88/ 07682 (43) International Publication Date: 6 October 1988 (06.10.88)
(21) International Application Number: PCT/US88/00641 (22) International Filing Date: 23 February 1988 (23.02.88) (31) Priority Application Number: 034,225 (32) Priority Date: 2 April 1987 (02.04.87) (33) Priority Country: US (71) Applicant: P B DIAGNOSTIC SYSTEMS, INC. [US/US]; 750 Main Street, Cambridge, MA 02139 (US). (72) Inventors: ARNOST, Michael, J. ; 29 Paddock Lane, North Andover, MA 01845 (US). MENEGHINI, Frank, A. ; 123 Claremont Avenue, Arlington, MA 02174 (US). PALUMBO, Paul, S. ; 271 Cherry Street, West Newton, MA 02165 (US). STROUD, Stephen, G. ; 15 Dunbar Avenue, Medford, MA 02155 (US).			(74) Agent: MACCARONE, Gaetano, D.; Polaroid Corp., Patent Dept., 549 Technology Square, Cambridge, MA 02139 (US). (81) Designated States: AU, DK, FI, JP, NO. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> A. O. J. P. 1 DEC 1988 <div style="border: 1px solid black; padding: 5px; text-align: center;">AUSTRALIAN - 2 NOV 1988 PATENT OFFICE</div>
(54) Title: FLUORESCENT CONJUGATES AND BIOLOGICAL DIAGNOSTIC ASSAY			
(57) Abstract <p>There are provided novel fluorescent conjugates comprising a rhodamine dye moiety and a biologically active moiety. In addition, there are provided methods for determining an analyte in a biological fluid.</p> <div style="border: 1px solid black; padding: 5px; text-align: center;"><p>This document contains the amendments made under section 49 and is correct for printing.</p></div>			

- 1 -

FLOURESCENT CONJUGATES AND BIOLOGICAL DIAGNOSTIC
ASSAY .BACKGROUND OF THE INVENTION

It is known in the biological diagnostic assay field to utilize conjugates of biologically active moieties with a detectable, signal-generating dye moiety which may be, for example, a moiety which emits electromagnetic radiation, e.g., a fluorescent, chemiluminescent or bioluminescent moiety. The biologically active moiety may be: a DNA probe, e.g., a labeled DNA probe of the type used in detecting complementary DNA sequences; an enzyme; an enzyme inhibitor; an antigen; an antibody; a hapten, etc.

In recent years much attention has been focused on labeled-reagent immunoassays for the detection of body fluid components such as antigens, hormones, infectious agents, serum antibodies and the like. Consequently, the patent literature includes many disclosures of various assays involving a labeled-reagent reaction between antigens and antibodies to provide a detectable signal which may be a change in color, emission of electromagnetic radiation, etc. These assays involve an immunological interaction between a ligand and an antiligand wherein at least one of the two reactants contains a substance or a precursor of a substance which can provide the detectable signal as a function of the immunological ligand - antiligand interaction.

One class of labels commonly used in such assays are fluorescent dyes or fluorophores. Both heterogeneous and homogeneous specific binding assays employing fluorescent-labeled conjugates are well known in the art. In general, it is desirable that fluorescent labels for use in such assays have a relatively long emission wavelength, e.g., above 500 nm. In addition, it is desirable that the labels have a large Stokes shift, be stable under the assay conditions, be relatively free of non-specific interference both from materials in solution and the moiety to which the label is conjugated and provide high quantum yields.


The present invention relates to novel fluorescent conjugates comprising a rhodamine dye moiety linked to a biologically active moiety and their use in biological diagnostic assay elements and processes.

It is therefore an object of this invention to provide novel fluorescent conjugates which include a biologically active moiety and a fluorescent dye moiety.

A further object is to provide biological diagnostic assay elements and processes.

BRIEF SUMMARY OF THE INVENTION

These and other objects and advantages are accomplished in accordance with the invention by providing novel fluorescent conjugates which are represented by the formula



wherein W, X, Y and Z are the same or different and each is represented by $-(CH_2)_a(CHR_4)(CH_2)_b-$;

a and b each independently is an integer of from 0 to 4, provided that the sum of a + b is an integer of from 1 to 4;

5 m and n each is 0 or 1, provided that one of m and n is 0 and one of m and n is 1;

p and q each is 0 or 1, provided that one of p and q is 0 and one of p and q is 1;

10 R, R₁, R₃ and R₄ each independently is hydrogen, a substituent including a hydrophilic group such as, for example, a carboxylic acid, a polyalcohol, a sulfonic acid or the like, or a substituent including a biologically active moiety such as an antigen, an antibody or the like;

R₂ is CO₂[⊖], SO₃[⊖]; or a substituent including a biologically active moiety such as those described above;

15 provided that at least one of R, R₁, R₂, R₃ and R₄ is a substituent including a biologically active moiety and at least one of the remaining R, R₁, R₃ and R₄ is a substituent including a hydrophilic group;

20 A is a counterion or counterions to balance the charges produced by the conjugate moiety; and x is 0 or 1.

25 According to a second embodiment of the invention there is provided a fluorescent diagnostic assay comprising combining in an assay medium: a sample suspected of containing an analyte; and members of a signal producing system; one of said members comprising a conjugate of a member of a specific binding pair and a fluorescent compound as defined above.

30 According to a further embodiment of the invention there is provided a diagnostic assay element adapted to receive a sample of a biological fluid and to provide a detectable signal as a function of an analyte which may be present in said fluid, said assay element including a fluorescent conjugate as defined above.

35 It will be understood that where the conjugate moiety is neutral overall no counterion is needed. The counterion, A, may be any biologically acceptable anion or cation such as, for example, chloride, sulfate, diphenylphosphate, trifluoroacetate, trimethylammonium, sodium, potassium, calcium and the like. It will also be understood that when the conjugate moiety has a net overall charge greater than one, the charges may be balanced by one or more counterions. For example, where the conjugate



- 3a -

moiety has a net overall charge of +2, these charges can be balanced by two chloride ions or one sulfate ion. .


It should be noted that by "hydrophilic group", as used in the specification and claims herein, is meant a group which will improve the solubility of the molecule in water. Typical suitable hydrophilic groups which may be

TMS/913c



-4-

incorporated in the novel fluorescent compounds of the invention include: carboxylic acids ($-\text{COOH}$); polyethers such as those represented by $\text{-(OCH}_2\text{CH}_2\text{)}_c\text{-O Et}$ where c is an integer of from 1 to 20 such as polyethylene oxide; poly-alcohols which are represented by $-\text{CH}_2\text{-(CHOH)}_d\text{-CH}_2\text{OH}$ where d is an integer of from 1 to 20; primary, secondary or tertiary amines which are represented by $-\text{NR}_5\text{R}_6$ where R_5 and R_6 each independently is hydrogen, alkyl, preferably having from 1 to 6 carbon atoms, aryl such as phenyl or

polyamines such as $-(\text{CH}_2)_2\text{-N}$  $\text{-N-(CH}_2\text{)}_2\text{NH}_2$; sulfonic

acids ($-\text{SO}_3\text{H}$); phosphonic acids or esters which are represented by $\text{-(CH}_2\text{)}_e\text{-PO(OR}_7\text{)(OR}_8\text{)}$ where e is an integer of from 1 to 8 and R_7 and R_8 each independently is hydrogen, alkyl, preferably having from 1 to 6 carbon atoms or aryl such as phenyl; phosphates represented by $\text{-(CH}_2\text{)}_e\text{-OPO(OH)}_2$; phosphate esters represented by $\text{-(CH}_2\text{)}_e\text{-OPO(OH)(OR}_9\text{)}$ where R_9 is alkyl, preferably having from 1 to 6 carbon atoms or aryl such as phenyl; phosphinic acids represented by $\text{-(CH}_2\text{)}_e\text{-PO(OH)R}_{10}$ where R_{10} is alkyl, preferably having from 1 to 6 carbon atoms; boronic acids which are represented by $-\text{R}_{11}\text{-B(OH)}_2$ where R_{11} is $\text{-(CH}_2\text{)}_e$ or aryl such as phenyl; and borinic acids represented by $-\text{R}_{11}\text{-B(OH)R}_{10}$. As will be shown in more detail below, the compounds of the invention may include one or more of the same hydrophilic groups or they may include more than one different type of hydrophilic group.

The novel fluorescent conjugates within Formula I have emission maxima which are above 500 nm, typically in the range of from about 500 nm to about 650 nm.

Generally, the novel conjugates of the invention include at least one biologically active moiety which can be attached directly to the dye chromophore or which can be attached to the dye chromophore through a divalent

-5-

achromophoric linking group. By the term "achromophoric linking group" is meant one which does not cause any appreciable shift in the spectral absorption characteristics of the dye moiety. Thus, in Formula I, where any of R, R₁, R₂, R₃ or R₄ is a substituent including a biologically active moiety, such substituent may include a divalent achromophoric linking group to link the dye moiety to the biologically active moiety. Such a linkage should be non-conjugated.

The biologically active moiety may be any such as, for example, an antigen, an antibody, a hapten, a DNA probe, an Fab fragment, etc.

Typical functional groups which are useful as coupling groups which can be attached to the dye molecule, and the substituents of the biologically active moiety with which such coupling groups are reactable to provide the achromophoric linking group within the labeled conjugates, are:

<u>COUPLING GROUP</u>	<u>SUBSTITUENT OF BIOLOGICALLY ACTIVE GROUP</u>
N-hydroxysuccinimide esters	amino groups (α -amino, lysine)
Imidoester	amino groups
Aldehydes	amino groups
Mixed anhydrides	nucleophilic groups
Isothiocyanates	nucleophilic groups
2,4-dichloro-5-triazine	nucleophilic groups
Diazonium salts	tryptamine, histamine
Bromoacetyl	histamine, SH
Maleimido	SH
Activated disulfide bonds (e.g. 2-pyridyldisulfides)	SH

-6-


Many other linking groups may be incorporated into the conjugates of the invention. For example, the hydrophilic groups mentioned above are substantially achromophoric and certain of these can be derivatized and utilized as suitable linking groups. For example, an $-NH_2$ group can be converted to an amide as a result of attaching the biologically active moiety (BIO) to it, i.e., $-NHCO-BIO$. Further, in another embodiment a hydrophilic group may be attached to the linking group. For example, in the case of a primary amine, one of the hydrogen atoms is replaced by a biologically active moiety attached to it as described above and the other hydrogen atom can be replaced by a hydrophilic group such as, for example, $-(CH_2)_2PO_3H_2$. Thus, it will be appreciated that the linking group, while serving as the means for attaching the dye moiety to the biologically active moiety, can also have a hydrophilic group attached to it. In addition, the linking group may also function as a hydrophilic group such as, for example, in the case of $-NH-BIO$ and $-PO_2(OH)-BIO$.

The labeled fluorescent conjugates of the invention are useful in various applications including diagnostic assays which are based on an energy transfer mechanism to activate the fluorescent label. The fluorescent dye moieties typically have maximum absorption, λ_{max} , of from about 500 nm to about 650 nm, exhibit Stokes shifts of about 15 - 20 nm and have high quantum yields of about 0.7 - 0.8. These dye moieties advantageously offer a number of positions of attachment for biologically active moieties and/or solubilizing groups. The presence of such solubilizing groups can help to avoid undesirable nonspecific binding of the conjugates to components present in biological fluids such as, for example, plasma proteins.

DESCRIPTION OF THE PREFERRED EMBODIMENT

A preferred class of conjugates according to the invention is represented by the formula

-7-




(II)

 $(A)_x$

where R_{12} , R_{13} , R_{14} and R_{15} may be the same or different and each independently is hydrogen, a substituent including a hydrophilic group such as any of those described above, or a substituent including a biologically active moiety such as any of those described above; and R_2 , R_3 , A and x are as previously defined.

Another preferred class of conjugates according to the invention is represented by the formula




(III)

 $(A)_x$


wherein R_2 , R_3 , R_{12} , R_{13} , R_{14} , R_{15} , A and x are as previously defined.

-8-


As stated previously, in the conjugates of the invention the biologically active moiety may be attached to the fluorescent dye moiety at various positions. In a preferred embodiment the biologically active moiety is included within substituent R_2 (Formula I). The biologically active moiety is preferably attached through a linkage which is a carboxamido piperazinyl derivative represented by the formula



Thus, in this preferred embodiment R_2 is represented by



or



The attachment of the biologically active moiety to the linkage may be through any appropriate position on that moiety. For example, where the biologically active moiety is theophylline it may be attached to the linkage through the 3- or 8- positions.

-9-

The labeled conjugates of the invention may be used in any of many applications such as, for example, in diagnostic assays such as competitive binding assays or immunoassays or in immune response reactions employing labeled reagents. In a preferred embodiment, the conjugates are employed in drug monitoring applications such as for theophylline, phenytoin, etc. or in hormone monitoring applications such as thyroxine (T4). The particular assays in which the conjugates of the invention find utility are well known, e.g., immunometric assays, competitive binding assays, etc. and therefore extensive discussion of such assays is not required here. In such known diagnostic tests, or assays, a biological reaction or interaction results in the generation of a detectable signal. For instance, in a typical immunoassay carried out in a multilayer assay element, an analyte - containing sample comprising a body fluid such as serum or whole blood is applied to a surface of the element. The fluid is typically passed through a filtering medium to remove interfering species and/or cells and then diffuses to a layer containing the labeled biologically active conjugate to produce an immunological reaction or interaction in accordance with the particular system of the assay element and this reaction or interaction in turn generates a detectable signal which is a function of the analyte in the sample fluid. The signal so generated may in less sophisticated systems provide only a qualitative determination of the presence of analyte or, in more sophisticated systems, it may provide a semi-quantitative measurement of the analyte. In such a system, the biologically active conjugate containing the detectable signal - generating moiety may be a so-called label-protein conjugate, i.e., a protein such as an antigen, antibody or Fab fragment "labeled" with, or containing, the dye moiety.

-10-

A typical multilayer assay element according to the invention comprises a support layer, which may be transparent, carrying at least one reagent layer in which there is provided the labeled conjugate of the invention. Also, in the reagent layer(s) there is provided any other reagent which is necessary for the particular signal generating system being exploited for the particular assay. These elements may also include other layers to provide various functions which are known in the art such as, for example: a layer to receive the sample and provide an even distribution of the sample components to the underlying reagent layer(s); a light-blocking, or screen, layer to assist in the detection of the signal by separating the layer in which the signal generating species is located from other layers of the element thus preventing undesirable interference with the detection of the signal; etc.

The conjugates of the invention may also be used for fluorescent staining of cells. The cells may then be observed under a microscope, the presence of the fluorescent conjugate being indicative of the presence of a specific determinant site. Further, the conjugates may be used for the deletion, separation or other application in a fluorescent activated cell sorter.


The conjugates of the invention may be prepared by reactions which are known to those skilled in the art and these will be apparent from the specific examples provided below herein. Accordingly, extensive discussion of such processes is not required here.

The invention will now be described further in detail with respect to specific preferred embodiments by way of Examples, it being understood that these are intended to be illustrative only and the invention is not limited to the specific materials, compositions or processes described therein.

- 11 -

EXAMPLE I

A mixture of 1.9g (13.0 mmole) of 7-hydroxyquinoline and 100 mg Pt_2O in 75 ml of 95% ethanol was hydrogenated overnight. The mixture was suction filtered through diatomaceous earth and the filtrate evaporated under reduced pressure. The resulting reddish-brown oil slowly crystallized to afford a quantitative yield of




(VII)

which was stored in the dark under nitrogen.

^1H NMR (CDCl_3): δ 1.85 (quint., 2H, $J=6$ Hz), 2.65 (t, 2H, $J=6$ Hz); 3.23 (t, 2H, 6 Hz); 4.65 (b.s., 2H), 5.95 (d, 1H, $J=3$ Hz); 6.1 (dd, 1H, $J_1=90$ Hz, $J_2=3$ Hz), 6.75 (d, 1H, $J=9$ Hz). M.S. (M^+ 149).

The crude product (VII) (28 mmole) was combined neat in a dry flask with 4.16g (28 mmole) of phthalic anhydride and 1.9g (14 mmole) of fused ZnCl_2 and the resulting mixture was heated in an oil bath at 150°C under nitrogen for 2 hours. The solid mass was cooled to room temperature, pulverized and extracted with warm water and suction filtered. The resulting red solid was taken up in 250 ml of 18% aq. HCl , warmed on a steam bath and several ml of conc. HCl added to reach solubility. The solution was slowly cooled to room temperature and then stored in a freezer for 2 days. The resulting crystalline product was suction filtered, washed with excess 1N HCl and dried under vacuum to give 2.65g (42% yield) of


- 12 -



as a purple powder. Titration with potassium-*t*-butoxide suggested that the product was a bis-HCl salt (M^+ 410 free base).

Potassium-*t*-butoxide (1.56g, 13.9 mmole) was added in one portion to a stirred solution of 2.0g of the previous product (VIII) in 200 ml of dry DMF at 0°-5°C under nitrogen. A cyan color formed and subsequently dissipated. (Note: subsequently it was found to be more convenient to add the potassium-*t*-butoxide to a point where the cyan color persists and then add one more equivalent). Another 0.5g (4.5 mmole) of potassium-*t*-butoxide was added and the resulting cyan solution stirred for 45 minutes. To this solution there was added, dropwise over a 5 minute period, a solution of 2.2 ml (13.4 mmole) *t*-butylbromoacetate in 10 ml DMF and the resulting mixture warmed to room temperature. The solvent was then removed under high vacuum followed by taking up the residue in CH_2Cl_2 , filtering through diatomaceous earth and evaporating the filtrate. The product was purified by chromatography on silica gel using 10% CH_3OH/CH_2Cl_2 as the eluent to give 2.0g (70% yield) of


- 13 -



as a magenta powder.

¹H NMR (CDCl₃): 1.5 (s, 18H), 1.9 (m, 4H), 2.55 (t, 4H, J=6 Hz), 3.4 (t, 4H, J=6 Hz), 3.4 (t, 4H, J=6 Hz), 3.9 (bs., 4H), 6.23 (s, 2H), 6.34 (s, 2H), 7.1 - 7.2 (m, 1H), 7.5-7.75 (m, 2H), 8.0-8.2 (m, 1H).


A mixture of 370 mg (0.58 mmole) of (IX) and 193 mg (0.58 mmole) of



(which was made from the corresponding 8-carboxypropyl theophylline and piperazine via trimethylacetyl mixed anhydride coupling) in 10 ml DMF was cooled to -30°C. Diphenylphosphoryl azide (160 µl, 0.75 mmole) was added to the stirred solution under nitrogen and the bath allowed to warm slowly to room temperature. After 4 days the solution was poured into excess ethyl ether, the liquid decanted from the oil and the oil chromatographed on silica gel using 10-15% CH₃OH/CH₂Cl₂ to give 421 mg (61% yield) of

- 14 -


(XI)



as the diphenylphosphate salt ($\text{X} = (\text{PhO})_2\text{PO}_2^-$); ($m/e=956$ FAB^+).

^1H NMR (CDCl_3) was complex but consistent with the structure of the product.

A solution of 421 mg (0.35 mmole) of (XI) in 10 ml CH_2Cl_2 was cooled to about 5°C and treated with 2 ml of trifluoroacetic acid. The resulting mixture was stirred under nitrogen for 30 minutes and then at room temperature overnight. The product was isolated by evaporation of the solvent and purified by chromatography on silica gel with 15% - 30% $\text{CH}_3\text{OH}/10\%$ $\text{AcOH}/\text{CH}_2\text{Cl}_2$ as the eluent to give the desired conjugate



-15-

where R' is -OH and R'' is $-O^{\ominus}$, as a hygroscopic solid in 63% yield: (M^+ 843); 1H NMR (CD_3OD , $CDCl_3$) complex but consistent with counterion being internal carboxylate compensated); λ_{max} (pH7 buffer) 568 nm ($\epsilon = 107,073$).

$C_{45}H_{46}N_8O_9 \cdot (H_2O)_4$ requires 59.07% C, 5.95% H and 12.25% N. Elemental analysis found 59.26% C, 5.71% H and 12.25% N.

EXAMPLE II

Conjugates XIII (XII where R' is $-NH(CH_2)_2SO_3H$) and R'' is $-NH(CH_2)_2SO_3^{\ominus}$) and XIV (XII where R' = R'' and each is $-N(CH_3)CH_2(CHOH)_4CH_2OH$) were synthesized from XII via diphenylphosphoryl azide (DPPA) coupling with taurine and N-methyl-d-glucamine, respectively. Thus, 1 mmole of XII was combined with 3 mmoles of taurine (or 3 mmoles of N-methyl-d-glucamine) and 5 mmoles of triethylamine in the case of taurine (or 2 mmoles in the case of N-methyl-d-glucamine) in 1/2 ml of dry DMF. To the cooled solutions ($-30^{\circ}C$) there were added 3 mmoles DPPA in one portion, the bath slowly warmed to room temperature and stirred overnight. The products were isolated by evaporation under vacuum and purified by reverse phase chromatography.


Conjugate XIII exhibited λ_{max} (pH7 buffer) 558 nm ($\epsilon = 74,900$). Conjugate XIV exhibited λ_{max} (pH7 buffer) 555 nm ($\epsilon = 60,300$).

EXAMPLE III

To a flamed/ N_2 cooled 100 ml round bottom flask equipped with an inlet for N_2 atmosphere there was added 2.0g (4.1×10^{-3} mole) of bis rhodamine HCl salt (VIII) along with 50 ml of dry DMSO (48 hours over 3A sieves). The flask was immersed in a water bath at ambient temperature and then 1.89g (1.68×10^{-2} mole) of t-butoxide potassium salt were added in one portion with stirring. The red-violet colored reaction mixture was stirred for 2 hours at ambient temperature. Propane sultone (2.54g, 2.08×10^{-2} mole) was added in one portion and the reaction


-16-

mixture stirred for an additional 14 hours at ambient temperature. The crude reaction mixture was evaporated under high vacuum and the resulting solid was triturated with CH_3CN and then with ethyl ether prior to chromatographic purification using a reverse phase support, (C_{18} silica prepared according to Journal of Organic Chemistry, 48, 1983, page 3589) and 30% $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ as the eluent to yield 2.3g (72% yield) of a magenta powder, tris(3-sulfopropyl) rhodamine, represented by the formula




The structure of the product was confirmed by a 300 MHz NMR spectrum.

The tris(3-sulfopropyl) rhodamine (2.3g) was stirred in 30 ml of aqueous 1N NaOH for 1 hour under nitrogen. To this solution there was added 30 ml of 1N HCl and the solvent then evaporated to dryness under high vacuum. The resulting solid was dissolved in a small volume of water and applied to a pad of C_{18} silica. The salts were removed by washing with water. The desired bis (3-sulfopropyl) rhodamine carboxylic acid was removed from the pad by elution with CH_3OH , the solvent removed by evaporation under vacuum and the solid product triturated with CH_3CN followed by drying under vacuum to give 1.67g (86% yield) of bis (3-sulfopropyl) rhodamine carboxylic acid*, a purple powder represented by the formula



*The compound is hygroscopic and should be stored under nitrogen.


Bis (3-sulfopropyl) rhodamine carboxylic acid (50 mg, 7.67×10^{-5} mole) was added to a flamed/ N_2 cooled round bottom flask together with 2-3 ml of dry DMF and stirred at ambient temperature under nitrogen. Triethylamine (64 μ l, 46.4 mg, 4.6×10^{-4} mole) was added followed by pivaloyl chloride (28.2 μ l, 27.6 mg, 2.3×10^{-4} mole) and the mixture stirred for 2 hours. The reaction was monitored by TLC using a piperidine quench on aliquots. Piperazine (66 mg, 7.67×10^{-4} mole) was added to the formed mixed anhydride and the reaction mixture stirred for an additional 14 hours. The solvent was then removed under high vacuum and the crude mixture was purified on a silica gel column using C_{18} silica with 30% CH_3OH/H_2O as the eluent to give bis (3-sulfopropyl) rhodamine piperazinamide, represented by the formula



-18-


The structure of the product was confirmed by NMR spectral data (300 MHz). Quantitative analysis was consistent with a hexahydrate. The product deliquesces readily and should be stored under high vacuum or nitrogen.

The mixed anhydride of 3-(carboxypropyl) theophylline (which was prepared following the procedure described in Jour. of Org. Chem., 45 (9) 1980, page 1711) was formed in a flamed/ N_2 cooled round bottom flask under nitrogen by addition of pivaloyl chloride (14.5 μ l, 14.5 mg, 1.20×10^{-4} mole) and triethylamine (16.7 μ l, 12.1 mg, 1.20×10^{-4} mole) to 3-(carboxypropyl) theophylline (28.6 mg, 1.20×10^{-4} mole) in 6 ml of dry DMF at 0°C . The mixture was stirred for 1 1/2 hours at 0°C and then transferred to a separate flamed/ N_2 cooled round bottom flask containing bis (3-sulfopropyl) rhodamine piperazinamide (43.4 mg, 6.01×10^{-5} mole) under nitrogen. The reaction mixture was stirred for 12 hours at ambient temperature. Thin layer chromatography showed an incomplete reaction so 2 more equivalents of the mixed anhydride were added to the reaction mixture. The solvent was removed under high vacuum and the crude product was purified by chromatography in accordance with the procedure previously described using 40% $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ as the eluent to give 40 mg (68.7% yield) of the rhodamine/3-(carboxypropyl) theophylline conjugate represented by the formula



- 19 -

where BIO is




The structure of the product was confirmed by a 300 MHz NMR spectrum, $m/e = 958$ FAB⁺.

EXAMPLE IV

L - thyroxine sodium salt, from Cal Biochem, (200 mg, 0.25 mmole) was added to a stirred solution of acetic anhydride (24 μ l, 0.25 mmole) in 2 ml DMF at room temperature under nitrogen. Triethylamine (35 μ l, 0.25 mmole) was then added and the resulting mixture stirred overnight. The solvent was removed under high vacuum, the residue taken up in 2 ml CH₃OH and then 1N HCl added dropwise, with stirring, to form a white precipitate. The supernatant liquid was decanted and the solid dried under vacuum to give 180 mg (88% yield) of


(XIX)



¹H NMR (CD₃OD - CDCl₃): 2.02 (s, 3H), 2.8 - 3.2 (m, 2H), 4.70 (b.t., 1H, J=7 Hz), 7.1 (s, 2H), 7.7 (s, 2H); M.S. (M⁺ 819).

-20-

Trimethylacetyl chloride (30 μ l, 0.24 mmole) was added dropwise to a stirred solution of 180 mg (0.22 mmole) of XIX and triethylamine (34 μ l, 0.24 mmole) in 2 ml DMF at 0° - 5°C. The resulting mixture was stirred under nitrogen for 1 hour and then added dropwise to a cold solution of 95 mg (1.10 mmole) piperazine in 1 ml DMF. The mixture was warmed to room temperature, stirred for 2 hours and then evaporated to dryness. The residue was triturated with CH₃OH, filtered, triturated with H₂O, filtered and dried to give 41 mg (21% yield) of




M.S. (M^+ 887).

A mixture of IX (41 mg, 0.064 mmole) and 57 mg of XX (0.064 mmole) in 1 ml DMF, at -30°C under nitrogen, was treated in one portion with 18 μ l (0.083 mmole) of diphenylphosphoryl azide. The resultant mixture was allowed to warm to room temperature and stirred overnight. The volatile matter was removed under high vacuum and the residue chromatographed on silica gel with 10% AcOH/20% CH₃OH/CH₂Cl₂ to give 12 mg (13% yield) of

-21-

(XXI)




conjugate XXII (XXI) where $R' = R''$ and each is $-\text{OC}(\text{CH}_3)_3$ and X is diphenylphosphate).

Conjugate XXIII (XXI where R' is $-\text{OH}$ and R'' is O^\ominus) was made from XXII following the same procedure used for XII


EXAMPLE V

1-(carboxyethyl)phenobarbital (50 mg, 1.64×10^{-4} mole) was dissolved in 2 ml of dry DMF with stirring under N_2 . The solution was cooled in an ice water bath and triethylamine (25 μl , 1.75×10^{-4} mole) added in one portion. Pivaloyl chloride (22 μl , 1.75×10^{-4} mole) was added to the mixture in one portion. Within several minutes a precipitate was observed and the mixture was stirred at 5°C for 1 hour. The mixture was then added slowly, dropwise, to a solution of piperazine (70.6 mg, 8.20×10^{-4} mole) in 5 ml of dry DMF with stirring under N_2 . The reaction mixture was stirred with cooling in an ice water bath for 1 hour and then at room temperature for 1 hour followed by concentration of the solvent under high vacuum at room temperature. The semi-solid residue was charged onto a silica gel column and eluted with 10% $\text{CH}_3\text{OH}/1\% \text{NH}_4\text{OH}/\text{CH}_2\text{Cl}_2$. The desired product fractions were concentrated under vacuum to give 45.1 mg (74% yield) of

- 22 -



Triethylamine (19 μ l, 1.33×10^{-4} mole) was added in one portion to a cooled solution ($\sim 3^{\circ}\text{C}$) of 78 mg (1.21×10^{-4} mole) of IX in 2 ml of dry DMF. Pivaloyl chloride (17 μ l, 1.33×10^{-4} mole) was added to the solution in one portion with cooling. A precipitate was observed almost immediately and the mixture was stirred for 1 hour at reduced temperature. The mixture was then added quickly, dropwise, to a solution of 45 mg (1.21×10^{-4} mole) of XXIV and triethylamine (19 μ l, 1.33×10^{-4} mole) in 2 ml of dry DMF. The resulting solution was stirred for 1 hour at reduced temperature and 1 hour at room temperature. The solution was then concentrated to a solid under high vacuum. The solid was purified on a silica gel column by eluting with 1:1 ethyl acetate/acetone to give the unreacted dye (24 mg, 31%). Elution with 10% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ gave 65.3 mg (54.3%) of



-22-


XXVI (XXV where $R' = R''$ and each is $-\text{OC}(\text{CH}_3)_3$ and X is chloride).

Compound XXVI (65.3 mg, 6.57×10^{-5} mole) was stirred in 1.5 ml of trifluoroacetic acid at room temperature under nitrogen for 1 1/2 hours and the solvent then concentrated under vacuum. The residue was charged onto reverse phase silica gel and eluted with 40% $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ and then with 60% $\text{CH}_3\text{OH}/\text{H}_2\text{O}$ to give numerous fractions with mixtures of products. The fractions exhibiting $R_f = 0.79$ with reverse phase silica gel were concentrated under vacuum and dried to give 6.1 mg of XXVII (XXV where R' is $-\text{OH}$ and R'' is $-\text{O}^\ominus$). Subsequent syntheses indicated that elution from normal phase silica gel with 10% $\text{CH}_3\text{OH}/10\%$ $\text{HOAc}/\text{CH}_2\text{Cl}_2$ provides better recovery.

EXAMPLE VI

A flask containing 40 ml of glacial acetic acid was cooled in a cold water bath and 1.9g (0.03 mole) of sodium cyanoborohydride was added portionwise with stirring and constant cooling. After H_2 evolution had ceased, 1.0g (0.0075 mole) of 4-hydroxyindole was added and the resulting solution was stirred at room temperature for 3 hours.

The reaction mixture was then slowly poured into a stirred solution of 50g sodium carbonate in 400 ml H_2O . The crude product was extracted out with ethyl acetate. The solvents were removed on the rotary evaporator and the residue was chromatographed on silica gel (10% $\text{EtOAc}/\text{CH}_2\text{Cl}_2$) to yield 723 mg (71%) of



(XXVIII)


-24-

4-hydroxyindoline (XXVIII) as a white powder.

^1H NMR (CDCl_3): δ 2.83 (t, 2H), 3.43 (t, 2H), 5.13 (b.s., 1H), 5.9 - 6.1 (m, 2H), 6.77 (t, 1H), 8.80 (s, 1H) $m/e = 135$.

A suspension of 1.6g (12.1 mmole) of mono-methylsuccinate in 20 ml of dry toluene was stirred at room temperature and 140 mg (3.7 mmole) of sodium borohydride was added. No evolution of gas was observed. The suspension was treated with 100 mg (0.74 mmole) of XXVIII and the temperature of the reaction mixture was slowly raised to 60°C , during which time gas evolution started and total solution was achieved.

After 2 hours at 60° , the reaction solution was cooled to room temperature, then quenched into 200 ml saline, and the product was extracted out with EtOAc. The solvents were removed on the rotary evaporator to give a crude product which was chromatographed on silica gel (5% EtOAc/ CH_2Cl_2). The product containing fractions were combined and evaporated, leaving a white solid. This solid was dissolved in CH_2Cl_2 and washed with 5% sodium bicarbonate solution. The layer was dried over sodium sulfate and then evaporated to yield 35 mg (20%) of XXIX as a pale oil.




(XXIX)

^1H NMR (CDCl_3): δ 1.89 (q, 2H), 2.39 (t, 2H), 2.75 - 3.2 (m, 4H), 3.37 (t, 2H), 3.63 (s, 3H) 5.95 - 6.15 (m, 2H), 6.88 (t, 1H) $m/e = 236$ (FAB^+).

-25-

Compound XXIX (32 mg, 0.14 mmole) was combined neat in a dry flask with phthalic anhydride (20.1 mg, 0.14 mmole) and fused ZnCl_2 (9 mg, 0.07 mmole) and the resulting mixture was heated in an oil bath at 150°C under nitrogen for two hours. The resulting red mass was cooled to room temperature, then chromatographed on silica gel, using 3% MeOH - 5% MeOH/ CH_2Cl_2 as eluant. The product containing fractions were combined and evaporated to yield 18 mg (45%) of XXX as a purple solid.




^1H NMR ($\text{CDCl}_3 + \text{CD}_3\text{OD}$): δ 1.97 (m, 4H), 2.40 (t, 4H), 3.3 - 3.7 (m, 8H), 3.63 (s, 6H), 4.03 (t, 4H), 6.57 (d, 2H, $J = 9$ Hz), 7.02 (d, 2H, $J = 9$ Hz), 7.3 (m, 1H), 7.75 (m, 2H), 8.3 (m, 1H). $m/e = 583$

A mixture of 18 mg (0.031 mmole) of XXX and 10.3 mg (0.031 mmole) of compound X in 1.5 ml DMF was cooled to -30°C . Diphenylphosphoryl azide (10 mg, 0.036 mmole) was added to the stirred solution under nitrogen and the reaction mixture was slowly allowed to warm to ambient temperature, then stirred for 60 hours. The solvents were removed under high vacuum and the purple residue was chromatographed on silica gel (5% MeOH - 15% MeOH/ CH_2Cl_2) to yield 32 mg (91%) of XXXI as a purple solid.

-26-


(XXXI)



^1H NMR ($\text{CDCl}_3 + \text{CD}_3\text{OD}$) was complex but consistent with the structure of the product.

A solution of 30 mg (0.026 mmole) of XXXI in 2 ml ethanol was treated dropwise with 1.0 ml of 0.1 N NaOH solution and the resulting solution was heated at 30°C under nitrogen until TLC showed complete hydrolysis (about 2 hours). The excess solvents were removed under high vacuum. The residue was stirred with 5% HOAc solution, and the excess solvents were again removed under vacuum. The crude product was purified by chromatography on silica gel with 10% - 20% MeOH/5% HOAc/ CH_2Cl_2 as the eluant to yield 14 mg (62%) of the conjugate XXXII as a purple powder.

(XXXII)



-27-

$m/e = 872$ (FAB^+).

Visible spectrum: λ_{max} (pH 7 buffer): 600 nm,
 $\epsilon = 58000$.

1H NMR ($CD_3OD + CDCl_3$) was complex but consistent with the counterion being internal carboxylate compensated.

EXAMPLE VII

To further illustrate the utility of the biological fluorescent conjugates of the invention a thyroxine (T4) immunoassay was carried out. The following reagents were used in the assay:

Reagent A solution: 50 mmoles HEPES buffer (pH 7.2); 10 mmoles Na_2 EDTA; 0.02% 8-anilino-naphthalene sulfonate (ANS); 0.1% bovine serum albumin (BSA); and 0.05% NaN_3 .

Reagent B solution: reagent A and 5% polyethylene glycol (PEG; NW 6000).

Calibrator solutions were made having 1, 25, 50, 100, 200 and 400 ng T4/ μl of Reagent, A, respectively. The calibrator solutions (200 μl) were each combined with 200 μl of mouse monoclonal anti-T4 antibody (Behringwerke AG 49/7), 0.15 mmole Ig G, in Reagent A and 200 μl of a solution of conjugate, 0.17 mmole, in Reagent A. The mixture was incubated for 60 minutes at room temperature. Subsequently, 200 μl of 2% mouse normal serum in Reagent B and 200 μl of goat anti-mouse Ig G antibody (1/16 dilution of Calbiochem Cat. No. 401210) in Reagent B were added and the mixture further incubated for 15 minutes at room temperature.

The mixtures were then centrifuged for 15 minutes at 3000g and the supernatant liquid decanted. The fluorescence of the free conjugate in the supernatant liquid was measured on a Perkin Elmer MPF 44 Fluorophotometer with excitation at 565 nm and the emission at 590 nm measured. Table I shows the results obtained:

-28-

TABLE I


<u>Thyroxin</u> <u>(ng/ul)</u>	<u>Free Conjugate</u> <u>(%)</u>
1	19.0
25	25.4
50	39.8
100	71.8
200	84.2
400	87.0

The standard curve exhibited good dose response in the 70-110 ng T4/ml range of interest.

Although the invention has been described with respect to specific preferred embodiments, it is not intended to be limited thereto but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims. For example, the rings of the rhodamine label moiety of the conjugates can be appropriately substituted further such as with the solubilizing groups disclosed. Thus, analogs possessing the advantageous features of the conjugates of the present invention will be considered as equivalents thereof for the purposes of the claims herein.

The claims defining the invention are as follows:

1. A fluorescent diagnostic assay comprising combining in an assay medium: a sample suspected of containing an analyte; and members of a signal producing system; one of said members comprising a conjugate of a member of a specific binding pair and a fluorescent compound, said conjugate represented by the formula



wherein W, X, Y and Z each independently is $-(CH_2)_a(CHR_4)(CH_2)_b-$;

R, R₁, R₃ and R₄ each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety;

R₂ is $-CO_2^-$, $-SO_3^-$ or a substituent including a biologically active moiety;

provided that at least one of R, R₁, R₂, R₃ and R₄ is a substituent including said biologically active moiety and at least one of the remaining R, R₁, R₃ and R₄ is said hydrophilic group;

a and b each independently is an integer of from 0 to 4, provided that the sum of a + b is an integer of from 1 to 4;

m and n each is 0 or 1 provided that one of m and n is 0 and the other is 1;

p and q each is 0 or 1 provided that one of p and q is 0 and the other is 1;


A is a counterion or the counterions to balance the overall charges on the conjugate moiety; and x is 0 or 1; and



separating bound conjugate from free conjugate;
measuring the level of the fluorescent signal of said bound or free conjugate; and

relating said level of said signal to the amount of said analyte in said sample.

2. The assay as defined in claim 1 wherein said conjugate is represented by the formula



where R₁₂, R₁₃, R₁₄ and R₁₅ each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R₂, R₃, R₁₂, R₁₃, R₁₄ and R₁₅ is a substituent including said biologically active moiety and at least one of the remaining of R₃, R₁₂, R₁₃, R₁₄ and R₁₅ is said hydrophilic group.


3. The assay as defined in claim 2 wherein R₂ is a substituent including a biologically active moiety.

4. The assay as defined in claim 3 wherein R₁₂ is a substituent including a hydrophilic group.

5. The assay as defined in claim 4 wherein R₁₃ is a substituent including a hydrophilic group.

6. The assay as defined in any of claims 4 and 5 wherein said hydrophilic group is a carboxylic acid, a polyether, a polyalcohol, an amine, a sulfonic acid, a phosphonic acid, a phosphonic ester, a phosphate, a phosphate ester, a phosphinic acid, a boronic acid or a borinic acid.

7. The assay as defined in claim 1 wherein said conjugate is represented by the formula



wherein R_{12} , R_{13} , R_{14} and R_{15} each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said biologically active moiety and at least one of the remaining of R_3 , R_{12} , R_{13} , R_{14} and R_{15} is said hydrophilic group.

8. The assay as defined in claim 7 wherein R_2 is a substituent including a biologically active moiety.

9. The assay as defined in claim 8 wherein R_{12} is a substituent including a hydrophilic group.

10. The assay as defined in claim 9 wherein R_{13} is a substituent including a hydrophilic group.

11. The assay as defined in claim 9 or 10 wherein said hydrophilic group is a carboxylic acid, a polyether, a polyalcohol, an amine, a sulfonic acid, a phosphonic acid, a phosphonic ester, a phosphate, a phosphate ester, a phosphinic acid, a boronic acid or a borinic acid.

12. The assay as defined in any one of claims 1 to 11, wherein said member of a specific binding pair is said analyte or an analogue thereof.


13. The assay as defined in any one of claims 1 to 12, wherein said biologically active moiety is said analyte or analogue thereof.



14. The assay as defined in claim 12 or claim 13, wherein one of R , R_1 , R_2 , R_3 and R_4 is a substituent including said analyte or an analogue thereof.

15. The assay as defined in claim 12 or claim 13, wherein one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said analyte or an analogue thereof.

16. A diagnostic assay element adapted to receive a sample of a biological fluid and to provide a detectable signal as a function of an analyte which may be present in said fluid, said assay element including a fluorescent conjugate represented by the formula



wherein W, X, Y and Z each independently is $-(CH_2)_a(CHR_4)(CH_2)_b-$;

R , R_1 , R_3 and R_4 each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety;

R_2 is $-CO_2^-$, $-SO_3^-$ or a substituent including a biologically active moiety;

provided that at least one of R , R_1 , R_2 , R_3 and R_4 is a substituent including said biologically active moiety and at least one of the remaining of R , R_1 , R_3 and R_4 is a substituent including said hydrophilic group;

a and b each independently is an integer of from 0 to 4, provided that the sum of $a + b$ is an integer of from 1 to 4;

m and n each is 0 or 1 provided that one of m and n is 0 and the other is 1;


p and q each is 0 or 1 provided that one of p and q is 0 and the other is 1;

A is a counterion or the counterions to balance the overall charges on the conjugate moiety; and x is 0 or 1.

17. The diagnostic element as defined in claim 16 which includes a support carrying at least one reagent layer.

18. The diagnostic element as defined in claim 17 which includes the binding partner of said biologically active moiety present in said conjugate.

19. The assay element as defined in claim 16 wherein said conjugate is represented by the formula



wherein R_{12} , R_{13} , R_{14} and R_{15} each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said biologically active moiety and at least one of the remaining of R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said hydrophilic group.


20. The assay element as defined in claim 19 wherein R_2 is a substituent including a biologically active moiety.

21. The assay element as defined in claim 20 wherein R_{12} is a substituent including a hydrophilic group.

22. The assay element as defined in claim 21 wherein R_{13} is a substituent including a hydrophilic group.

23. The assay element as defined in any of claims 21 and 22 wherein said hydrophilic group is a carboxylic acid, a polyether, a polyalcohol, an amine, a sulfonic acid, a phosphonic acid, a phosphonic ester, a phosphate, a phosphate ester, a phosphinic acid, a boranic acid or a borinic acid.

24. The assay element as defined in claim 16 wherein said conjugate is represented by the formula



wherein R_{12} , R_{13} , R_{14} and R_{15} each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said biologically active moiety and at least one of the remaining of R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said hydrophilic group.

25. The assay element as defined in claim 24 wherein R_2 is a substituent including a biologically active moiety.

26. The assay element as defined in claim 25 wherein R_{12} is a substituent including a hydrophilic group.


27. The assay element as defined in claim 26 wherein R_{13} is a substituent including a hydrophilic group.



28. The assay element as defined in any of claims 26 and 27 wherein said hydrophilic group is a carboxylic acid, a polyether, a polyalcohol, an amine, a sulfonic acid, a phosphonic acid, a phosphonic ester, a phosphate, a phosphate ester, a phosphinic acid, a boranic acid or a borinic acid.

29. The diagnostic element as defined in any one of claims 16 to 28, wherein said biologically active moiety is selected from the group consisting of an antigen, an antibody, a hapten, an Fab fragment and a DNA probe.

30. A fluorescent conjugate represented by the formula



wherein W, X, Y and Z each independently is $-(CH_2)_a(CHR_4)(CH_2)_b-$;

R, R₁, R₃ and R₄ each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety;

R₂ is $-CO_2^-$, $-SO_3^-$ or a substituent including a biologically active moiety;

provided that at least one of R, R₁, R₂, R₃ and R₄ is a substituent including said biologically active moiety and at least one of the remaining R, R₁, R₃ and R₄ is a substituent including said hydrophilic group;


a and b each independently is an integer of from 0 to 4, provided that the sum of a + b is an integer of from 1 to 4;

m and n each is 0 or 1 provided that one of m and n is 0 and the other is 1;

p and q each is 0 or 1 provided that one of p and q is 0 and the other is 1;

A is a counterion or the counterions to balance the overall charges on the conjugate moiety; and x is 0 or 1.

31. The fluorescent conjugate as defined in claim 30 which is represented by the formula




wherein R_{12} , R_{13} , R_{14} and R_{15} each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said biologically active moiety and at least one of the remaining of R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said hydrophilic group.

32. The fluorescent conjugate as defined in claim 31 wherein R_2 is a substituent including a biologically active moiety.

33. The fluorescent conjugate as defined in claim 30 which is represented by the formula





wherein R_{12} , R_{13} , R_{14} and R_{15} each independently is hydrogen, a substituent including a hydrophilic group (as hereinbefore defined) or a substituent including a biologically active moiety, provided that at least one of R_2 , R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said biologically active moiety and at least one of the remaining of R_3 , R_{12} , R_{13} , R_{14} and R_{15} is a substituent including said hydrophilic group.

34. The fluorescent conjugate as defined in claim 33 wherein R_2 is a substituent including a biologically active moiety.

35. A fluorescent conjugate as defined in any one of claims 30 to 34, wherein said biologically active moiety is selected from the group consisting of an antigen, an antibody, a hapten, an Fab fragment and a DNA probe.

36. A fluorescent diagnostic assay substantially as hereinbefore described with reference to any one of the Examples.

37. A diagnostic assay element substantially as hereinbefore described with reference to any one of the Examples.

38. A fluorescent conjugate substantially as hereinbefore described with reference to any one of the Examples.

DATED this THIRD day of MAY 1990

PB Diagnostic Systems, Inc.

Patent Attorneys for the Applicant

SPRUSON & FERGUSON



INTERNATIONAL SEARCH REPORT

International Application No PCT/US 88/00641

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁴: G 01 N 33/533; G 01 N 33/52; C 07 D 491/14

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

IPC⁴ G 01 N 33/00; C 07 D 491/00

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	EP, A, 0050684 (SYVA CO.) 5 May 1982, see abstract; page 4, paragraph 2; page 26, line 34 - page 27, line 35; page 40, line 5 - page 43, line 6 --	1, 2, 4-6
Y	US, A, 4622400 (P.R. HAMMOND) 11 November 1986, see column 2, formulae II, IIC & IIE	1, 2, 4-6
A	--	1, 25
A	Journal of Immunological Methods, vol. 50, 1982, (NL) J.A. Titus et al.: "Texas-Red, a hydro- philic, red-emitting fluorophore for use with fluorescein in dual parameter flow microfluorometric and fluorescence microscope studies" pages 193-204, see the whole document --	1, 25

* Special categories of cited documents: ¹⁴

"A" document defining the general state of the art which is not
considered to be of particular relevance

"E" earlier document but published on or after the international
filing date

"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or
other means

"P" document published prior to the international filing date but
later than the priority date claimed

"T" later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention

"X" document of particular relevance; the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step

"Y" document of particular relevance; the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search
18th August 1988

Date of Mailing of this International Search Report

29 SEP 1988

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

 P.C.G. VAN DER PUTTEN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Clinical Chemistry, vol. 31, no. 3, March 1985 (Winston-Salem, North Carolina, US) Ilkka Hemmälä: "Fluoroimmunoassay and immunofluorometric assays", pages 359-370, see page 361, column 1, paragraphs 2-4, column 2, paragraph 2; page 362, table 1; examples 2-5 --	1,12-15,25
Y	Analytical Chemistry, vol. 55, no. 4, April 1983 (Washington, DC, US) B. Walter: "Dry reagent chemistries in chemical analysis", pages 498A-514A, see the whole article --	1,12-15,25
A,P	Chemical Abstracts, vol. 107, no. 7, 17 August 1987 (Columbus, Ohio, US) M.C. Garnett et al.: "Tetramethyl rhodamine isothiocyanate-human serum albumin-antibody conjugates: a useful reagent for the assessment of endocytosis of cell-surface antigens", see page 564, column 1, abstract 57037z & Biochem. Soc. Trans., vol. 15, no. 3, 1987, pages 431-432 --	1,25
A	Chemical Abstracts, vol. 100, no. 11, 12 March 1984 (Columbus, Ohio, US) M.J. Geisow et al.: "Fluorescein conjugates as indicators of subcellular pH. A critical evaluation", see page 262, column 2, abstract 82277r & Exp. Cell Res., vol. 150, no. 1, 1984, pages 29-35 -----	1,25